Bilateral polysegmentary pneumonia caused by SARS-CoV-2 in a transplanted liver recipient
- Authors: Ishenko R.V.1, Golovincki S.V.1, Akhmedianov A.R.1, Voskanyan S.E.2, Kolyshev I.Y.2
-
Affiliations:
- Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia
- A.I. Burnazyan Federal Medical Biophysical Center of the Federal Medical and Biological Agency of Russia
- Issue: Vol 11, No 2 (2020)
- Pages: 101-106
- Section: Case reports
- URL: https://journals.rcsi.science/clinpractice/article/view/35121
- DOI: https://doi.org/10.17816/clinpract35121
- ID: 35121
Cite item
Abstract
Background. In December 2019, the humanity met a previously unknown infectious disease (COVID-19) caused by a new coronavirus called SARS-CoV-2. An important role in the treatment of COVID-19 belongs to anti-inflammatory and immunosuppressive drugs. In this regard, the cases of the disease in patients undergoing long-term immunosuppressive therapy, for example, organ transplant recipients, are of particular interest. We present our clinical observation of COVID-19 in a liver recipient patient, which, apparently, is the first in the Russian Federation.
Clinical case description A 54-year-old man, 10 years ago at the A.I. Burnazyan Center underwent transplantation of the right lobe of the liver after resection of hepatocellular carcinoma, T2N0M0, and due to liver cirrhosis as a result of НСV hepatitis. At the time of hospitalization, he had been constantly receiving immunosuppressive monotherapy with everolimus. The patient was transferred to an infectious disease hospital due to a positive PCR test for SARS-CoV-2 RNA. No signs of respiratory failure were found upon admission. Subsequently, a mild course of COVID-19 was observed, without signs of an acute inflammatory reaction, with normal CRP values and a slight increase of ferritin. 7 days after the treatment, the patient was discharged for outpatient observation.
Conclusion. This clinical case is of interest not only by the success of the treatment of the new coronavirus infection COVID-19 in an immunocompromised patient — a recipient of a liver transplant, but also by the fact that the disease manifested itself primarily as a transient increase in hepatic aminotransferases, which can be attributed to the gastrointestinal manifestations of COVID-19.
Full Text
##article.viewOnOriginalSite##About the authors
Roman V. Ishenko
Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia
Email: ishenkorv@rambler.ru
ORCID iD: 0000-0003-0260-6922
MD
Russian Federation, MoscowSergei V. Golovincki
Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia
Email: lungtranspl@gmail.com
ORCID iD: 0000-0001-6898-5393
MD
Russian Federation, MoscowArtur R. Akhmedianov
Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia
Author for correspondence.
Email: rbertvich-artur@rambler.ru
ORCID iD: 0000-0003-2099-9344
MD
Russian Federation, MoscowSergei E. Voskanyan
A.I. Burnazyan Federal Medical Biophysical Center of the Federal Medical and Biological Agency of Russia
Email: voskanyan_se@mail.ru
ORCID iD: 0000-0001-5691-5398
MD, PhD, Professor
Russian Federation, MoscowIlya Yu. Kolyshev
A.I. Burnazyan Federal Medical Biophysical Center of the Federal Medical and Biological Agency of Russia
Email: diffdiagnoz@mail.ru
ORCID iD: 0000-0002-6254-130X
MD, PhD
Russian Federation, MoscowReferences
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
- Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–971. doi: 10.1056/NEJMc2001468.
- Holshue ML, De Bolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi: 10.1056/NEJMoa2001191.
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi: 10.1038/s41422-020-0282-0.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. doi: 10.1056/NEJMoa2001282.
- Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China [e-pub ahead of print]. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa248.
- Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405–407. doi: 10.1016/j.healun.2020.03.012.
- Li F, Cai J, Dong N. First Cases of COVID-19 in heart transplantation from China. J Heart Lung Transplant. 2020;39(5):496–497. doi: 10.1016/j.healun.2020.03.006.
- Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020. doi: 10.1111/ajt.15941.
- Liu H, He X, Wang Y, et al. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation [published online ahead of print, 2020 Apr 10]. Hepatol Int. 2020;1–5. doi: 10.1007/s12072-020-10043-z.
- Chen D, Yang B, Zhang Y, et al. Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report. Medicine (Baltimore). 2020;99(24):e20481. doi: 10.1097/MD.0000000000020481.
- Hoehl S, Rabenau H, Berger A, et al. Evidence of SARS-CoV-2 infection in returning travelers from wuhan, China. N Engl J Med. 2020;382(13):1278–1280. doi: 10.1056/NEJMc2001899.